Coherus Announces Resubmission Of Biologics License Application Supplement For UDENYCA ONBODY To The FDA For Review
Portfolio Pulse from Benzinga Newsdesk
Coherus has resubmitted the Biologics License Application Supplement for UDENYCA ONBODY to the FDA for review. This follows the satisfactory resolution of the FDA's review of inspection findings at the third-party filler.
October 05, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus has resubmitted the Biologics License Application Supplement for UDENYCA ONBODY to the FDA. This could potentially lead to approval and increased revenues for the company.
The resubmission of the Biologics License Application Supplement for UDENYCA ONBODY to the FDA by Coherus is a positive development for the company. If the FDA approves the application, it could lead to increased revenues for Coherus. Therefore, this news is highly relevant and important for investors in CHRS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100